ArticleFrontiers in oncology2023

BCLXL PROTAC degrader DT2216 targets secondary plasma cell leukemia addicted to BCLXL for survival.

Ophélie Champion et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.